Clinical Trials

    Showing 1 - 10 of 10 Immune System Diseases

    A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

    Status: Open Not Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1... Read more >

    A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis (ADAPT oculus)

    Status: Open Not Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years... Read more >

    A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants wil... Read more >

    An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

    Status: Open Not Enrolling

    Investigator: Sai ravi kiran Pingali

    Study Coordinator:

    Phone:

    NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose ... Read more >

    Global Study of Del-desiran for the Treatment of DM1 (HARBOR)

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the ... Read more >

    Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that leve... Read more >

    Myotonic Dystrophy Compilation of Clinical Findings

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work evaluatio... Read more >

    Protective Genetic Factors Against Neurological Diseases

    Status: Open Not Enrolling

    Investigator: Jun Li

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small clus... Read more >

    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator: Delrose Vernon

    Phone: 346.238.9068

    Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG (gMG... Read more >

    RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

    Status: Enrolling

    Investigator: Bing Liao

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), an... Read more >